Biochemical and biopharmaceutical properties of PEGylated uricase

International Journal of Pharmaceutics

Volumn 387, Issue 1-2, 2010, Pages 215-222

  da Silva Freitas, Débora ^a   Spencer, Patrick Jack ^b   Vassão, Ruth Camargo ^c   Abrahão Neto, José ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^c INSTITUTO BUTANTAN   (Brazil)

Author keywords

Gout; Hyperuricemia; PEGylation; Physico chemical stability; Urate oxidase; Uricase

Indexed keywords

CARBONIC ACID; METHOXYPOLYETHYLENEGLYCOL 4 NITROPHENYL CARBONIC ACID; METHOXYPOLYETHYLENEGLYCOL 4,6 DICHLORO S TRIAZINE; UNCLASSIFIED DRUG; URATE OXIDASE;

ABSORPTION SPECTROSCOPY; AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; COVALENT BOND; ENZYME ACTIVITY; ENZYME SUBSTRATE; IMMUNE RESPONSE; IMMUNOGENICITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; RABBIT; TEMPERATURE;

ANIMALS; CANDIDA; CIRCULAR DICHROISM; DRUG CARRIERS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; MALE; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; RABBITS; RECOMBINANT PROTEINS; TEMPERATURE; URATE OXIDASE;

EID: 77649183731     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.11.034     Document Type: Article

References (44)

1. Altman K.I., Smull E.S., Barron G. A new method for the preparation of uricase and the effect of uricase on the blood uric acid levels of the chickens. Arch. Biochem. Biophys. 1959, 21:1158-1165.
2. Arora K., Saxena S.V., Gupta R.K., Gupta S.K., Yakhmi J.V., Pandey M.K., Chand S., Malhotra B.D. Improved performance of polyaniline-uricase biosensor. Anal. Chim. Acta 2007, 594:17-23.
3. Bailon P., Berthold W. Polyethylene glycol-conjugate pharmaceutical proteins. Pharm. Sci. Technol. Today 1998, 1:352-356.
4. Bomalaski J.S., Holtsberg F.W., Ensor C.M., Clarck M.A. Uricase formulated with polyethylene glycol (Uricase-PEG 20): biochemical rationale and preclinical studies. J. Rheumatol. 2002, 29:1942-1948.
5. Bomalaski J.S., Clark M.A. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr. Rheumatol. Rep. 2004, 6:240-247.
6. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
7. Brogard J.M., Counaros D., Frankhauser J., Stahl A., Stahl J. Enzymatic uricolysis: a study of the effect of fungal urate oxidase. Eur. J. Clin. Biol. Res. 1972, 17:890-895.
8. Brogard J.M., Stahl A., Stahl J. Enzymatic uricolysis and its use in therapy. Uric Acid (Handbook of Experimental Pharmacology) 1978, 51:515-524. Springer, New York.
9. Caliceti P., Veronese F.M., Jonak Z. Imunogenic and tolerogenic properties of monomethoxypoly(ethylene glicol) conjugate proteins. Farmaco 1999, 54:430-437.
10. Caliceti P., Schiavon O., Veronese F.M. Immunological properties of uricase conjugated to neutral soluble polymers. Bioconjug. Chem. 2001, 12:515-522.
11. Caliceti P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethyleneglycol) protein conjugates. Adv. Drug Deliv. Rev. 2003, 55:1261-1277.
12. Cammalleri L., Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int. J. Med. Sci. 2007, 4:83-88.
13. Cannella A.C., Mikuls T.R. Understanding treatments for gout. Am. J. Manag. Care 2005, 11:451-458.
14. Chen R.H.L., Abuchowski A., Van Es T., Palczuk N.C., Davis F.F. Properties of two urate oxidase modified by the covalent attachment of poly(ethylene glycol). Biochim. Biophys. Acta 1981, 660:293-298.
15. Chohan S., Becker M.A. Update on emerging urate-lowering therapies. Curr. Opin. Rheumatol. 2009, 21:143-149.
16. Chua C.C., Greenberg M.L., Viau A.T., Nucci M., Brenckman W.D., Hershfield M.S. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann. Intern. Med. 1988, 109:114-117.
17. Colloc'h N., el Hajji M., Bachet B., L'Hermite G., Schiltz M., Prangé T., Castro B., Mornon J.P. Crystal structure of the protein drug urate oxidase-inhibitor complex at 2.05Áresolution. Nat. Struct. Biol. 1997, 4:947-952.
18. Colloc'h N., Girard E., Dhaussy A.C., Kahn R., Ascone I., Mezouar M., Fourme R. High pressure macromolecular crystallography: the 140-MPa crystal structure at 2.3Á resolution of urate oxidase, a 135-kDa tetrameric assembly. Biochem. Biophys. Acta. 2006, 1764:391-397.
19. Colonna C., Conti B., Perugini P., Pavanetto F., Modena T., Dorati R., Ladarola P., Genta I. Site-directed PEGylation as successful approach to improve the enzyme replacement in the case of prolidase. Int. J. Pharm. 2008, 358:230-237.
20. Davis S., Park Y.K., Abuchowski A., Davis F.F. Hypouricaemic effect of polyethylene glycol modified urate oxidase. Lancet 1981, 8241:281-283.
21. Habeeb A.F. Determination on free amino groups in proteins by trinitrobensensulphonic acid. Anal. Biochem. 1966, 14:328-336.
22. Huang S.H., Shih Y.C., Wu C.Y., Yuan C.J., Yang Y.S., Li Y.K., Wu T.K. Detection of serum uric acid using the optical polymeric enzyme biochip system. Bios. Bioel. 2004, 19:1627-1633.
23. Koyama Y., Ichikawa T., Nakano E. Cloning, sequence analysis and expression in Escherichia coli of the gene enconding the Candida utilis urate oxidase (uricase). J. Biochem. 1996, 120:969-973.
24. Kurfurst M.M. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrphoresis. Anal. Biochem. 1992, 200:244-248.
25. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
26. London M., Hudson P.B. Uricolytic activity of purified uricase in two human beings. Science 1957, 125:937-938.
27. Mahler J.L. A new bacterial uricase for uric acid determination. Anal. Biochem. 1970, 38:348-358.
28. Malzert A., Boury F., Renard D., Robert P., Lavenant L., Benoi{dotless}t J.P., Proust J.E. Spectroscopic studies on poly(ethylene glycol)-lysozyme interactions. Int. J. Pharm. 2003, 260:175-186.
29. Masera G., Jankovic M., Zurlo A., Locasiulli M.R., Rossi M.D., Urdezo C., Recchia M. Urate-oxidase prophylaxias of uric acid-induced renal demange in childhood leukemia. J. Pediatr. 1982, 100:152-155.
30. Morille M., Passirani C., Letrou-Bonneval E., Benoit J.P., Pitard B. Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting. Int. J. Pharm. 2009, 379:293-300.
31. Nishimura H., Ashihara Y., Matsushima A., Inada Y. Modification of yeast uricase with polyethylene glycol: disappearance of binding ability towards anti-uricase serum. Enzyme 1979, 24:261-264.
32. Nishimura H., Matsushima A., Inada Y. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreacyivity towards anti-uricase serum and high enzymic activity. Enzyme 1981, 26:49-53.
33. Pasut G., Sergi M., Veronese F.M. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv. Drug Deliv. Rev. 2008, 60:69-78.
34. Schiavon O., Caliceti P., Ferruti P., Veronese F.M. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugate to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). Farmaco 2000, 55:264-269.
35. Sherman M.R., Saifer M.G.P., Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev. 2008, 60:59-68.
36. Soares L.S., Guimaraes G.M., Polakiewicz B., Pitombo R.N.M., Abrahao-Neto J. Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli l-asparaginase. Int. J. Pharm. 2002, 237:163-170.
37. Song S., Liu D., Peng J., Sun Y., Li Z., Gu J.R., Xu Y. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm. 2008, 363:155-161.
38. Treetharnmathurot B., Ovartlarnporn C., Wungsintaweekul J., Duncan R., Wiwattanapatapee R. Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin. Int. J. Pharm. 2008, 357:252-259.
39. Usuda N., Usman M.I., Reddy M.K., Hashimoto T., Reddy J.K., Rao M.S. Immunocytochemical localization of urate oxidase, fatty acyl-CoA oxidase, and catalase in bovine kidney peroxisomes. J. Histoch. Cytoch. 1988, 36:253-258.
40. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10:1451-1458.
41. Veronese F.M., Mero A. The impact of PEGylation on biological therapies. Bio. Drugs 2008, 22:315-329.
42. Volkl A., Baumgart E., Fahimi D. Localization of urate oxidase in the crystalline cores of rat liver peroxisomes by immunocytochemistry and immunoblotting. J. Histoch. Cytoch. 1988, 36:329-336.
43. Zappe H., Snell M.E., Bossard M.J. PEGylation of cyanovirin-N, an entry inhibitor of HIV. Adv. Drug Deliv. Rev. 2008, 60:79-87.
44. Zhou J., Cai Z.H., Li L., Kou C., Gao Y.F. Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris. Eur. J. Pharm. Biopharm. 2009, 72:412-417.